Joanne Edwards

List of Publications by Year
in descending order

191	10,095	36203	40881
papers	citations	51 h-index	93 g-index

198	198	198	15627
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletionâ€"Resistant Growth. Cancer Research, 2009, 69, 2305-2313.	0.4	763
2	The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. Cell, 2012, 151, 1185-1199.	13.5	561
3	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. Cancer Research, 2012, 72, 3457-3462.	0.4	518
4	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. British Journal of Cancer, 2003, 89, 552-556.	2.9	380
5	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
6	Senescent cells harbour features of the cancer epigenome. Nature Cell Biology, 2013, 15, 1495-1506.	4.6	300
7	Mannose impairs tumour growth and enhances chemotherapy. Nature, 2018, 563, 719-723.	13.7	282
8	Observer variation in immunohistochemical analysis of protein expression, time for a change?. Histopathology, 2006, 48, 787-794.	1.6	214
9	NF-ÎºB pathways in the development and progression of colorectal cancer. Translational Research, 2018, 197, 43-56.	2.2	164
10	High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients. American Journal of Pathology, 2010, 177, 2205-2215.	1.9	156
11	Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2009, 15, 3540-3549.	3.2	147
12	Gene amplifications associated with the development of hormone-resistant prostate cancer. Clinical Cancer Research, 2003, 9, 5271-81.	3.2	144
13	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. European Urology, 2014, 66, 32-39.	0.9	139
14	MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death and Disease, 2018, 9, 19.	2.7	134
15	The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 2012, 107, 864-873.	2.9	132
16	The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 2013, 109, 1676-1684.	2.9	124
17	Is PTEN loss associated with clinical outcome measures in human prostate cancer?. British Journal of Cancer, 2008, 99, 1296-1301.	2.9	123
18	The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU International, 2005, 95, 1320-1326.	1.3	118

#	Article	IF	Citations
19	The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU International, 2005, 95, 1327-1335.	1.3	113
20	Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. British Journal of Cancer, 2007, 97, 378-383.	2.9	110
21	Sphingosine 1-phosphate signalling in cancer. Biochemical Society Transactions, 2012, 40, 94-100.	1.6	109
22	Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells. Molecular and Cellular Biology, 2010, 30, 3827-3841.	1.1	94
23	The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2006, 12, 123-130.	3.2	93
24	Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. British Journal of Cancer, 2009, 100, 680-683.	2.9	93
25	Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient. Scientific Reports, 2018, 8, 14672.	1.6	93
26	Sleeping Beautyscreen revealsPpargactivation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8290-8295.	3.3	91
27	The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. British Journal of Cancer, 2014, 111, 157-165.	2.9	90
28	CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 2014, 127, 3893-901.	1.2	85
29	The NF-KB pathway and endocrine therapy resistance in breast cancer. Endocrine-Related Cancer, 2019, 26, R369-R380.	1.6	85
30	Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. Journal of Pathology, 2002, 198, 237-244.	2.1	83
31	HER2 and COX2 expression in human prostate cancer. European Journal of Cancer, 2004, 40, 50-55.	1.3	81
32	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 887-898.	0.9	80
33	Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e100759.	1.1	80
34	Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. British Journal of Cancer, 2008, 98, 1094-1101.	2.9	79
35	Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer, 2012, 106, 383-388.	2.9	78
36	SIRT2: Tumour suppressor or tumour promoter in operable breast cancer?. European Journal of Cancer, 2014, 50, 290-301.	1.3	78

#	Article	IF	Citations
37	Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 2013, 123, 1157-1175.	3.9	75
38	Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death and Disease, 2013, 4, e927-e927.	2.7	74
39	Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene, 2008, 27, 2978-2988.	2.6	72
40	Sphingosine 1-Phosphate Receptor 4 Uses HER2 (ERBB2) to Regulate Extracellular Signal Regulated Kinase-1/2 in MDA-MB-453 Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 35957-35966.	1.6	72
41	Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. Clinical Cancer Research, 2009, 15, 1487-1495.	3.2	71
42	Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. British Journal of Cancer, 2011, 104, 1920-1928.	2.9	70
43	Evaluation of a Tumor Microenvironmentâ€“Based Prognostic Score in Primary Operable Colorectal Cancer. Clinical Cancer Research, 2015, 21, 882-888.	3.2	69
44	The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. British Journal of Cancer, 2015, 113, 1066-1074.	2.9	67
45	The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. Journal of Pathology, 2004, 204, 153-158.	2.1	65
46	The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 231-241.	2.0	63
47	Breast cancer patientsâ€™ clinical outcome measures are associated with Src kinase family member expression. British Journal of Cancer, 2010, 103, 899-909.	2.9	61
48	Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 2012, 106, 1453-1459.	2.9	59
49	Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. British Journal of Cancer, 2016, 114, 562-570.	2.9	59
50	NFÎºB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 2012, 107, 1554-1563.	2.9	55
51	The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. British Journal of Cancer, 2016, 115, 156-163.	2.9	54
52	GRP78 upâ€regulation is associated with androgen receptor status, Hsp70â€“Hsp90 client proteins and castrateâ€resistant prostate cancer. Journal of Pathology, 2011, 223, 81-87.	2.1	53
53	RUNX2 in subtype specific breast cancer and mammary gland differentiation. DMM Disease Models and Mechanisms, 2014, 7, 525-34.	1.2	53
54	Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. Journal of Pathology, 2005, 205, 522-529.	2.1	52

#	Article	IF	Citations
55	The relationship between tumour site, clinicopathological characteristics and cancerâ€specific survival in patients undergoing surgery for colorectal cancer. Colorectal Disease, 2012, 14, 1493-1499.	0.7	52
56	Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. British Journal of Cancer, 2013, 108, 139-148.	2.9	52
57	HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16392-16397.	3.3	51
58	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clinical Science, 2019, 133, 181-193.	1.8	51
59	The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU International, 2008, 102, 756-761.	1.3	49
60	Inhibitory-ÎºB Kinase (IKK) Î± and Nuclear Factor-ÎºB (NFÎºB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets. Cells, 2018, 7, 176.	1.8	49
61	Routine Acid Decalcification of Bone Marrow Samples Can Preserve DNA for FISH and CGH Studies in Metastatic Prostate Cancer. Journal of Histochemistry and Cytochemistry, 2002, 50, 113-115.	1.3	48
62	The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 4397-4404.	0.7	47
63	SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Molecular Medicine, 2012, 4, 776-790.	3.3	46
64	Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. British Journal of Cancer, 2017, 116, 1444-1450.	2.9	46
65	The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. British Journal of Cancer, 2018, 118, 705-712.	2.9	46
66	The role of gamma delta T lymphocytes in breast cancer: a review. Translational Research, 2019, 203, 88-96.	2.2	46
67	Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients?. American Journal of Pathology, 2009, 175, 1389-1397.	1.9	45
68	MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discovery, 2021, 11, 1228-1247.	7.7	45
69	Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate, 2005, 64, 101-107.	1.2	42
70	Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology, 2010, 56, 203-211.	1.6	41
71	Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer, 2014, 14, 676.	1.1	41
72	Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU International, 2001, 88, 633-637.	1.3	40

#	Article	IF	Citations
73	The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. British Journal of Cancer, 2012, 106, 702-710.	2.9	40
74	The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. Cancer Treatment Reviews, 2012, 38, 943-955.	3.4	40
75	Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1â€phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptorâ€positive breast cancer. International Journal of Cancer, 2013, 132, 605-616.	2.3	40
76	Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host. Clinical Cancer Research, 2017, 23, 1698-1709.	3.2	38
77	Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cellular Signalling, 2019, 56, 15-22.	1.7	38
78	Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Frontiers in Oncology, 2012, 2, 168.	1.3	37
79	Targeting sphingosine kinase 1 in cancer. Advances in Biological Regulation, 2012, 52, 31-38.	1.4	37
80	The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clinical Pathology, 2013, 13, 31.	1.8	37
81	Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. British Journal of Cancer, 2008, 99, 1769-1774.	2.9	36
82	Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treatment Reviews, 2017, 57, 1-7.	3.4	36
83	Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. Journal of Pathology, 2002, 196, 380-385.	2.1	35
84	The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer. Annals of Surgical Oncology, 2017, 24, 1295-1303.	0.7	34
85	Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 2010, 19, 605-614.	1.9	33
86	Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene, 2018, 37, 4679-4691.	2.6	31
87	Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 2012, 107, 856-863.	2.9	30
88	Elevated LIM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation. Molecular Cancer Therapeutics, 2015, 14, 246-258.	1.9	30
89	Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 2016, 16, 229.	1.1	30
90	Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 122-128.	2.0	29

#	Article	IF	Citations
91	Prospective Study of the Role of Inflammation in Renal Cancer. Urologia Internationalis, 2012, 88, 277-281.	0.6	29
92	Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer. OncoImmunology, 2016, 5, e1098801.	2.1	29
93	A novel tumorâ€based epithelialâ€toâ€mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. International Journal of Cancer, 2019, 144, 150-159.	2.3	28
94	Gut Î³Î´ T cells as guardians, disruptors, and instigators of cancer. Immunological Reviews, 2020, 298, 198-217.	2.8	28
95	Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. British Journal of Cancer, 2011, 105, 1362-1369.	2.9	26
96	Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology, 2012, 61, 283-292.	1.6	26
97	IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFÎ²1-induced mesenchymal invasion. International Journal of Biochemistry and Cell Biology, 2013, 45, 2774-2785.	1.2	26
98	The Epidemiology and Risk Factors for Renal Cancer. Current Urology, 2013, 6, 169-174.	0.4	26
99	The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. British Journal of Cancer, 2016, 115, 967-973.	2.9	26
100	Activation of Î²-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 576-590.	0.4	26
101	Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology, 2012, 61, 675-684.	1.6	25
102	Is the biology of breast cancer changing? A study of hormone receptor status 1984â€“1986 and 1996â€“1997. British Journal of Cancer, 2009, 100, 807-810.	2.9	23
103	The in situ local immune response, tumour senescence and proliferation in colorectal cancer. British Journal of Cancer, 2013, 109, 2207-2216.	2.9	23
104	Inhibitory Kappa B Kinase Î± (IKKÎ±) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers. Journal of Medicinal Chemistry, 2017, 60, 7043-7066.	2.9	23
105	Interrelationships between Tumor Proliferative Activity, Leucocyte and Macrophage Infiltration, Systemic Inflammatory Response, and Survival in Patients Selected for Potentially Curative Resection for Gastroesophageal Cancer. Annals of Surgical Oncology, 2011, 18, 2604-2612.	0.7	22
106	The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?. Journal of Cancer Research and Clinical Oncology, 2012, 138, 723-728.	1.2	22
107	High IKKÎ± expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)â€positive breast cancer. International Journal of Cancer, 2017, 140, 1633-1644.	2.3	22
108	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. Biomolecules, 2020, 10, 1365.	1.8	22

#	Article	IF	Citations
109	Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. British Journal of Cancer, 2001, 85, 1894-1899.	2.9	21
110	RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. Cancer Research, 2020, 80, 2325-2339.	0.4	21
111	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 2019, 206, 91-106.	2.2	20
112	The relationship between hypoxia-inducible factor 1Î± (HIF-1Î±) and patient survival in breast cancer: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103231.	2.0	20
113	A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 2017, 130, 697-711.	1.2	19
114	Sprouty2 lossâ€induced IL 6 drives castrationâ€resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 2018, 10, .	3.3	19
115	The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. Cell Death and Differentiation, 2021, 28, 1563-1578.	5.0	19
116	The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. British Journal of Cancer, 2012, 106, 1187-1195.	2.9	17
117	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 283-296.	1.3	17
118	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2021, 7, 121-134.	1.3	17
119	The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. BJU International, 2002, 90, 573-578.	1.3	16
120	Bad expression influences time to androgen escape in prostate cancer. BJU International, 2007, 100, 691-696.	1.3	16
121	Is Src a Viable Target for Treating Solid Tumours?. Current Cancer Drug Targets, 2010, 10, 683-694.	0.8	16
122	Nuclear factor ÎºB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Human Pathology, 2012, 43, 1491-1500.	1.1	16
123	A Prospective Study of the Role of Inflammation in Bladder Cancer. Current Urology, 2013, 6, 189-193.	0.4	16
124	The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 2016, 7, 77607-77621.	0.8	16
125	Interactions between MAP kinase and oestrogen receptor in human breast cancer. European Journal of Cancer, 2013, 49, 1176-1186.	1.3	15
126	The relationship between members of the canonical NF-ÎºB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 2017, 8, 33002-33013.	0.8	15

#	Article	IF	Citations
127	Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. Oncotarget, 2017, 8, 4875-4887.	0.8	14
128	The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. BJU International, 2005, 96, 62-66.	1.3	13
129	Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. Journal of Cancer Research and Clinical Oncology, 2012, 138, 327-332.	1.2	13
130	Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. International Journal of Molecular Sciences, 2013, 14, 16656-16671.	1.8	13
131	The effect of postoperative complications on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 155, 103075.	2.0	13
132	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 2021, 28, 2970-2982.	5.0	13
133	Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. British Journal of Cancer, 2010, 102, 1503-1510.	2.9	12
134	Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer. Human Pathology, 2013, 44, 1688-1695.	1.1	12
135	Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. Molecular Carcinogenesis, 2016, 55, 1667-1677.	1.3	12
136	Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer. Oncotarget, 2016, 7, 70601-70612.	0.8	12
137	THEM6â€mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 2022, 14, e14764.	3.3	12
138	Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomarkers, 2012, 10, 91-99.	0.8	11
139	ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. British Journal of Cancer, 2018, 119, 323-329.	2.9	11
140	Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: Implications for treatment. Cellular Signalling, 2019, 54, 81-90.	1.7	11
141	Preoperative, biopsyâ€based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 30-39.	1.3	11
142	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 2021, 124, 786-796.	2.9	11
143	Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. British Journal of Cancer, 2010, 103, 1831-1834.	2.9	10
144	The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. International Journal of Cancer, 2019, 144, 2320-2329.	2.3	10

#	Article	IF	Citations
145	BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 2020, 39, 1797-1806.	2.6	10
146	Expression of Tumor Necrosis Factor Î± Converting Enzyme in Endocrine Cancers. American Journal of Clinical Pathology, 2008, 129, 735-743.	0.4	9
147	The Prognostic Role of the Non-Canonical Nuclear Factor-Kappa B Pathway in Renal Cell Carcinoma Patients. Urologia Internationalis, 2018, 101, 190-196.	0.6	9
148	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 2021, 16, 163.	1.2	9
149	The role of SRC family kinases in prostate cancer. Translational Oncogenomics, 2007, 2, 67-77.	1.7	9
150	An Increase in N-Ras Expression is Associated with Development of Hormone Refractory Prostate Cancer in a Subset of Patients. Disease Markers, 2008, 24, 157-165.	0.6	8
151	Body Mass Index Predicts Failure of Surgical Management in Benign Prostatic Hyperplasia. Urologia Internationalis, 2013, 90, 150-155.	0.6	8
152	Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. Journal of the National Cancer Institute, 2018, 110, 616-627.	3.0	8
153	The relationship between Î²-catenin and patient survival in colorectal cancer systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103337.	2.0	8
154	The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer. Cellular Signalling, 2019, 60, 91-99.	1.7	7
155	Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 596-606.	2.0	7
156	Reclassification of the Fuhrman grading system in renal cell carcinoma-does it make a difference?. SpringerPlus, 2013, 2, 378.	1.2	6
157	The Prognostic Use of Inflammation and Tissue Necrosis in Benign Prostatic Hyperplasia. Urologia Internationalis, 2013, 91, 19-25.	0.6	6
158	Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 2017, 8, 37172-37185.	0.8	6
159	Determining the prognostic significance of IKKÎ± in prostate cancer. Prostate, 2020, 80, 1188-1202.	1.2	5
160	Novel Methods of Risk Stratifying Patients for Metachronous, Pre-Malignant Colorectal Polyps: A Systematic Review. Critical Reviews in Oncology/Hematology, 2021, 164, 103421.	2.0	5
161	Heregulin Expression and Prognosis in Prostate Adenocarcinoma. Urologia Internationalis, 2011, 87, 363-368.	0.6	4
162	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naÃ¯ve prostate cancer. Prostate, 2020, 80, 1353-1364.	1.2	4

#	Article	IF	Citations
163	Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer. Clinical Science, 2022, 136, 521-535.	1.8	4
164	The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer. Journal of Histochemistry and Cytochemistry, 2022, 70, 479-494.	1.3	4
165	The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2013-2020.	1.2	3
166	The inflammatory microenvironment in screen-detected premaligant adenomatous polyps: early results from the integrated technologies for improved polyp surveillance (INCISE) project. European Journal of Gastroenterology and Hepatology, 2021, 33, 983-989.	0.8	3
167	Systematic review of tumour budding and association with common mutations in patients with colorectal cancer. Critical Reviews in Oncology/Hematology, 2021, 167, 103490.	2.0	3
168	Mutation and Polymorphism Detection: A Technical Overview. , 2003, 226, 287-294.		2
169	Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens. Cancer Biomarkers, 2011, 8, 1-9.	0.8	2
170	Is the Presence or Absence of Tumour Necrosis a Significant Predictor of Survival in Renal Cell Cancer?. Urologia Internationalis, 2012, 88, 79-83.	0.6	2
171	In reply to â€˜Hynes etÂal. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage <scp>II</scp>/<scp>III</scp> colon cancer in a large populationâ€based studyâ€™. Histopathology, 2017, 71, 326-327.	1.6	2
172	The relationship between oestrogen receptorâ€alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer. Histopathology, 2017, 70, 782-797.	1.6	2
173	Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 2022, , .	2.9	2
174	The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. Human Pathology, 2022, 127, 1-11.	1.1	2
175	Detection of Microsatellite Instability and Loss of Heterozygosity Using DNA Extracted from Formalin-Fixed Paraffin-Embedded Tumor Material by Fluorescence-Based Multiplex Microsatellite PCR. , 2003, 226, 301-308.		1
176	Microdissection and Extraction of DNA From Archival Tissue. , 2004, 97, 071-076.		1
177	Signal transduction and activator of transcription 3 (STAT3), host inflammatory responses and survival of patients with colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 606-606.	0.8	1
178	The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 581-581.	0.8	1
179	The relationship between members of the canonical NF-kB pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients. Histology and Histopathology, 2020, 35, 569-578.	0.5	1
180	Direct Kinase Assay Screening for Inhibitors of MAP Kinase. , 2001, 39, 583-588.		0

#	Article	IF	Citations
181	Phosphotyrosine Kinase Assays as a Prescreen for Inhibitors of EGFr. , 2001, 39, 577-581.		0
182	14 Role of androgen receptor gene amplification and protein expression in hormone refractory prostate carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 423-430.	0.0	0
183	Editorial Comment on: Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells. European Urology, 2007, 52, 1680-1681.	0.9	0
184	Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology?. Current Urology, 2013, 7, 24-27.	0.4	0
185	Reply to comment of â€œERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancerâ€• British Journal of Cancer, 2018, 119, 909-909.	2.9	0
186	Detection of Microsatellite Instability and Loss of Heterozygosity Using DNA Extracted from Formalin-Fixed Paraffin-Embedded Tumor Material by Fluorescence-Based Multiplex Microsatellite PCR. , 2003, , 301-308.		0
187	Recurrence in Bladder Cancer: A Molecular Dead End?. Current Genomics, 2003, 4, 417-434.	0.7	0
188	Association of the canonical NF-ÎºB pathway with clinical outcome measures in ER-negative breast cancer.. Journal of Clinical Oncology, 2013, 31, 588-588.	0.8	0
189	Abstract 976: Junctional adhesion molecule-A (JAM-A) expression is downmodulated by miR-21 during colorectal cancer progression. , 2014, , .		0
190	Comorbidity and systemic inflammation are independent prognostic factors in patients with colorectal cancer: A ScotScan collaborative study.. Journal of Clinical Oncology, 2019, 37, 707-707.	0.8	0
191	Local immune response in colon cancer: Indicative of good or poor prognosis?. Journal of Clinical Oncology, 2020, 38, 213-213.	0.8	0